Evidence map›Paper›PMID 41398476›Full record

ArticleNature neuroscience2026

A fully iPS-cell-derived 3D model of the human blood-brain barrier for exploring neurovascular disease mechanisms and therapeutic interventions.

Judit González-Gallego, Katalin Todorov-Völgyi, Stephan A Müller, Sophie Antesberger, Mihail Ivilinov Todorov, Rainer Malik, Rita Grimalt-Mirada, Carolina Cardoso Gonçalves, Martina Schifferer, Georg Kislinger and 11 more

Abstract read
In one paragraph

Article in Nature neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Novel advanced patient-derivedFrontiers in neurology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Judit González-Gallego *Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.ORCID http://orcid.org/0009-0005-0034-0595
Katalin Todorov-Völgyi *Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.ORCID http://orcid.org/0009-0007-8073-9524
Stephan A MüllerGerman Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.ORCID http://orcid.org/0000-0003-3414-307X
Sophie AntesbergerInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
Mihail Ivilinov TodorovInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-8627-1260
Rainer MalikInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
Rita Grimalt-MiradaInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
Carolina Cardoso GonçalvesInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
Martina SchiffererGerman Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-0500-8218
Georg KislingerInstitute of Neuronal Cell Biology, Technical University of Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-6559-7421
Isabel WeisheitInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
Barbara LindnerInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
Dennis CrusiusInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
Joseph KroegerInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
Mila BorriInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-6432-1888
Ali ErturkInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
Mark NelsonDepartment of Pharmacology, University of Vermont, Burlington, VT, USA.
Thomas MisgeldGerman Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.ORCID http://orcid.org/0000-0001-9875-6794
Stefan F LichtenthalerGerman Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.ORCID http://orcid.org/0000-0003-2211-2575
Martin DichgansInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany. Martin.Dichgans@med.uni-muenchen.de.ORCID http://orcid.org/0000-0002-0654-387X
Dominik PaquetInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany. dominik.paquet@med.uni-muenchen.de.ORCID http://orcid.org/0000-0003-2065-1639

Funding

Capillaries as a Sensory Web that Controls Cerebral Blood Flow in Health and DiseaseR35HL140027 · NHLBI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI NELSON, MARK T · 2019 to 2025
$6.3M
Ion Channel Dysfunction in Small Vessel Disease of the BrainR01NS110656 · NINDS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI NELSON, MARK T · 2019 to 2023
$2.6M
Lesions and loss of smooth muscle cells in brain underlies small vessel diseaseRF1NS128963 · NINDS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI JOUTEL, ANNE, NELSON, MARK T · 2022 to 2023
$2.2M
Lesions and Loss of Smooth Muscle Cells in Brain Underlies Small Vessel DiseaseR01NS128963 · NINDS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI MARK T NELSON · 2025 to 2026
$1.3M
Deutsche Forschungsgemeinschaft (German Research Foundation) DI 722/13-1; DI 722/16-1, BE 6169/1-1Deutsche Forschungsgemeinschaft (German Research Foundation) EXC 2145 SyNergy, ID 390857198Deutsche Forschungsgemeinschaft (German Research Foundation) Mi 694/9-1 A03-ID 428663564 FOR ImmunostrokeDeutsche Forschungsgemeinschaft (German Research Foundation) SFB TRR 274/2 2024 - 408885537 project Z01EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) SVDs@target, No 666881Fondation Leducq BRENDANHLBI NIH HHS R35 HL140027NINDS NIH HHS R01 NS110656NINDS NIH HHS R01 NS128963NINDS NIH HHS RF1 NS128963
6 · The paper itself

Abstract

Blood-brain barrier (BBB) integrity is critical for brain homeostasis, with malfunctions contributing to neurovascular and neurodegenerative disorders. Mechanistic studies on BBB function have been mostly conducted in rodent and in vitro models, which recapitulate some disease features, but have limited translatability to humans and pose challenges for drug discovery. Here we report on a fully human induced pluripotent stem (iPS)-cell-derived, microfluidic three-dimensional (3D) BBB model consisting of endothelial cells (ECs), mural cells and astrocytes. Our model expresses typical fate markers, forms a barrier in vessel-like tubes and enables perfusion, including with human blood. Deletion of FOXF2 in ECs, a major risk gene for cerebral small vessel disease, induced key features of BBB dysfunction, including compromised cell junction integrity and enhanced caveolae formation. Proteomic analysis revealed dysregulated endocytosis and cell junction pathways. Disease features phenocopied those seen in mice with EC-specific Foxf2 deficiency. Moreover, lipid-nanoparticle-based treatment with Foxf2 mRNA rescued BBB deficits, demonstrating the potential for drug development.

Indexed as

Blood-Brain BarrierInduced Pluripotent Stem CellsAnimalsAstrocytesCells, CulturedEndothelial CellsForkhead Transcription FactorsHumansMiceForkhead Transcription Factors

Identifiers

PMID41398476
PMCPMC12880921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.